Brett Coons, MD
Allergy · Jb Andrews, MDNPI 1780670281
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,398 of the $49,274 with a category attached, or 80.0%. Every reported general payment came from a single manufacturer, Phadia US Inc.. Reporting peaked in 2019 at $33,374 and has fallen 85.0% since, to $5,000 in 2021.
Across 36 payments — averaging $1368.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phadia US Inc.$49K
What the payments were for
- Speaking & faculty fees$39,39880%
- Travel & lodging$9,36619%
- Food & beverage$5111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phadia US Inc. | 36 | $49,274 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ImmunoCAP$49,166
How this compares
$49,274 in reported general payments places this provider in the 75th percentile of 29 allergy providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $129,661 |
| XolairOmalizumab | 31 | $125,283 |
| Dupixent SyringeDupilumab | 24 | $88,061 |
| NucalaMepolizumab | 15 | $78,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $24,528 |
| Cromolyn Sodium | 13 | $5,527 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 19 | $4,521 |
| Epinephrine | 18 | $3,821 |
| Azelastine Hcl | 64 | $2,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $1,287 |
| Montelukast Sodium | 67 | $1,208 |
| Ipratropium Bromide | 21 | $1,110 |
| Levocetirizine Dihydrochloride | 30 | $969 |
| Fluticasone Propionate | 39 | $838 |
| Betamethasone Dipropionate | 15 | $723 |
Paid to pharmacies, not to this prescriber.
Other allergy in Jb Andrews
- Priya NathJb Andrews$36
- Huamin LiWheaton$576K
- David GoldenBaltimore$197K
- Jody TverskyBaltimore$175K
- Sarbjit SainiBaltimore$174K
- Jonathan MatzWhite Marsh$147K
- Newton AdkinsonBaltimore$61K
- Peter CreticosBaltimore$22K
- David SchwartzBethesda$15K
- Asek MakiaMitchellville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.